Introduction
Relapsed diffuse large B-cell lymphoma (DLBCL) is often curable with high-dose therapy followed by auto-SCT. The Parma trial published in the pre-rituximab era is the only prospective randomized trial that established auto-SCT as the standard of care for eligible patients with relapsed refractory large B-cell lymphoma. 1 Several factors have been recognized as potential prognostic factors on transplant outcome. In non-Hodgkin's lymphoma (NHL), chemotherapy-sensitive disease, rituximab use either at initial diagnosis or at disease relapse, higher stem cell dose infusion and relapse greater than 12 months from the time of initial diagnosis have all been associated with improved outcome in patients undergoing auto-SCT. 2 ,3 Rituximab appears to improve the clinical outcome among patients undergoing high-dose therapy. 4 Recently it has been suggested that in patients who received auto-SCT for NHL, early recovery of the lymphocyte count, defined typically as an absolute lymphocyte count (ALC), at approximately 2-4 weeks following therapy has been associated with superior progression-free and OS in patients with NHL. 5, 6 Recovery of certain lymphocyte subsets suggests antitumor effects of self immune system. Specifically, early recovery of the natural killer cell subtype is of clinical significance and may be of prognostic value. 7 Previous studies that have identified early recovery of the lymphocyte count as an independent prognostic factor in predicting outcome, grouped several NHL histologies and did not specifically look at DLBCL. Long-term impact of rituximab, which is known to deplete B lymphocytes by binding to the CD20 domain, on early lymphocyte recovery and transplant outcome is lacking.
To address these major shortcomings, we evaluated patients with only diffuse large B-cell histology who were either rituximab naı¨ve or exposed to rituximab during their course of treatment followed by auto-SCT. In this study, we study the effects of early recovery of the lymphocyte count on patient outcome.
Patients and methods
Sample size and data collection One hundred and fifteen consecutive patients who underwent auto-SCT for relapsed DLBCL at a single institution between January 1998 and December 2008 were included in our systematic analysis. In order to perform clinically meaningful analysis of eight different variables on outcome, we determined that a sample size of at least 80 patients with complete data set was required for this study. This study was approved by the Vanderbilt University Institutional Review Board, and was in accordance with the United States Federal Regulations and Declaration of Helsinki. Patient's basic demographic data (age, gender), diseaserelated information (stage, grade, histology, age at diagnosis, stage at diagnosis, and pre-transplant therapy including presence or absence of rituximab), stem cell mobilization, conditioning regimens, engraftment, relapse and survival information were collected from the institution's electronic medical record and the social security death index. OS was defined as the percentage of patients alive at the completion of the study from diagnosis; death from any cause defined an event. The primary outcome analysis of this study was to determine if ALC at day 14 following an auto-SCT in patients with DLBCL can predict survival in the rituximab era.
DLBCL and histologies
Pathology that was reviewed and confirmed by hematopathologists at Vanderbilt University as DLBCL was included in the study. Patients with a diagnosis of T-cellrich large B cell, histiocytic-rich large B cell and follicular grade 3 with diffuse B cell-like features were also included. (10 9 /L) at 14 ± 1 day and 28 ± 1 day following autologous stem cell infusion were reported. Based on previous reports, it was determined that ALCs of 500 cells/mL at day 14 or 1000 cells/mL at day 28 were accepted cutoff values and could be dichotomized at this level of significance. 
Response criteria
Response criteria were based on guidelines from the International workshop on NHL. 8 CR was defined as complete radiological regression of all previous measurable disease or BM involvement. Partial response was defined as a reduction of 75% or greater reduction in the sum of the products of the longest and perpendicular diameter of measurable lesions. Based on these criteria, all data were individually verified regarding the best response status just before auto-SCT after administration of at least 2-4 cycles of chemotherapy.
Statistical analysis
Data was analyzed using SPSS software (v.17) (SPSS, Chicago, IL, USA). OS was reported by using Kaplan-Meier analysis. The difference between survival curves was tested for statistical significance using log-rank test. ALC at two time intervals (day 14 and day 28) were assessed as a continuous variable and dichotomized as either 500 cells/mL at day 14 or X1000 cells/mL at day 28, as previously described, or as X median lymphocyte count at day 14 (660 cells/mL) or day 28 (1020 cells/mL). Univariate analysis was performed on several other disease-related factors that were determined a priori. The factors analyzed include, remission status at the time of transplant, stem cell dose, number of chemotherapy regimens and prior rituximab exposure. w 2 -tests were used to determine the relationship between all categorical variables. Coxproportional hazard model was used for multivariable analysis. For association between continuous variables and categories Mann-Whitney U rank sum tests were used. All P-values reported were two-sided and statistical significance was declared at Po0.05. Cases with missing values were deleted from the final analysis.
Results

Patient characteristics
Baseline characteristics are reported in Table 1 . A total of one hundred and ten patients were included in the final analysis. Five patients were excluded because of lack of complete data sets. There were no significant differences among patients who were exposed to rituximab or those who were rituximab naı¨ve regarding age, sex, stage, pre-transplant remission status, number of pre-transplant regimens or conditioning regimens. Patients in the rituximab-exposed group did have a statistically significant number of patients with a diagnosis of DLBCLwith follicular grade 3 type. Sixty nine (78.4%) patients continued to be in CR at day 100 post-auto-SCT evaluation. Nineteen (21.6%) patients had persistent diseases requiring further therapy. Five patients (5.6%) died before day 100.
OS of patients following auto-SCT
The median survival of patients following auto-SCT for DLBCL was 78 months (range 3-186 months) (Figure 1a) . Among patients who were rituximab naı¨ve, the median survival was 50 months. In patients who had received rituximab therapy, the median survival was 98 months. At the time analysis, 69 (60.5%) patients were alive after median follow-up of 22.3 months (range 3.2-184.3 months). 18 (15.6%) patients were alive beyond 5 years post-auto-SCT. Prior rituximab showed a initial survival advantage, however on long-term follow-up, benefit was lost owing to late relapses (P ¼ 0.12) (Figure 1b) .
Univariate and multivariate analysis
In a univariate analysis from the time of auto-SCT, it appears that prior rituximab therapy significantly improved the overall outcome of patients with a hazard ratio of 0.5 (95% CI: 0.27-0.95) and P ¼ 0.03. In the multivariate analysis considering factors such as age, stage and ALC-14, prior rituximab therapy has no impact on patient outcome hazard ratio ¼ 0.71 (95% CI: 0.33-1.47) Tables 2 and 3 . The number of salvage regimens required before the transplant did not appear to have an impact on the overall outcome of patients in either group.
Pre-transplant disease status and outcome Forty (56%) patients were in CR and 25 (35%) in PR in the prior rituximab group compared with 13 (32%) and 17 (41%) in CR and PR, respectively, in the rituximab naı¨ve cohort. The difference in rates of CR did not reach statistical significance (P ¼ 0.07). Patients with complete response before the transplant appeared to have a trend towards improved survival (P ¼ 0.06) (Figure 2a ). The number of salvage regimens before auto-SCT also did not significantly impact the ALC or survival (Figure 2b ).
Lymphocyte recovery and outcome ALC at day þ 14 (ALC-14) and at day þ 28 (ALC-28) after auto-SCT were available on 90/110 patients and 85/110 patients, respectively. There was no significant difference in either ALC-14 or ALC-28 in patients who were rituximab exposed or naı¨ve (Figures 3a and b) . Neither ALC-14 nor ALC-28 was associated with a significant difference in transplant outcome, irrespective of rituximab status (Figure 4 ). Both ALC-14 and ALC-28 were analyzed as continuous and categorical variables without any significant difference in outcome. Analyzing ALC neither above or below 500 cells/mL nor above or below the median ALC resulted in any significant difference in outcome (data not shown). Patients with an ALC of 1000 cells/mL at day 28 had an initial improved survival compared with patients with less than 1000 cells/mL at day 28 (P ¼ 0.03). This survival benefit was however lost with long-term follow-up.
Discussion
Our results demonstrate that the early survival advantage seen post-auto-SCT in patients with an early lymphocyte recovery is lost with long-term follow-up. The advantages of prior rituximab exposure were also lost in the long term. Our data also showed prior rituximab had no impact on early lymphocyte recovery. The current standard of care for eligible patients with relapsed DLBCL is high-dose therapy followed by an auto-SCT. Previous data suggest that lymphocyte recovery greater than or equal to 500 cells/mL at day þ 14 after auto-SCT is an independent prognostic factor, and is associated with improved disease-free and OS in NHL as well as other hematological malignancies. 7, 9, 10 These studies however grouped patients with several histologies. The number of peripheral blood autograft absolute lymphocytes infused appear to correlate with day 15 ALC. 11 The role of rituximab on lymphocyte recovery and its effects on other lymphocyte subsets such as T cells and NK cells are largely unknown. Rituximab is known to cause lymphopenia by depleting the B cells. Rituximab does not appear to impact the T cells or NK cells. These effects may last for as long as 6 months for full recovery of lymphocytes. 12 In mantle cell lymphoma, the ALC at day 15 (ALC-15) following an auto-SCT was associated with a significant improvement in clinical outcome. ALC-15 X 500 cell/mL had an improved PFS and OS. 13 The exact mechanism as to why early lymphocyte recovery would lead to improved survival in patients following auto-SCT is unclear. It has been hypothesized that early effective immune recovery may contribute to the graft vs tumor effect. Our results however do not draw similar conclusions in DLBCL. The quantitative early recovery of lymphocytes is effective in eradicating residual disease as demonstrated by the early survival advantage. This does not, however, translate to prolonged disease-free interval suggesting the loss of the ability of immune reconstituting cells to maintain the graft vs tumor effect. A recently published study by Porrata et al. 7 included lymphocyte subset analysis in patients who were all treated with prior rituximab therapy, reported the NK cell subset was associated with superior PFS and OS among a heterogeneous group of NHL patients.
Our study lacks data on lymphocyte subsets. We, however, report our analysis in a large homogenous population with the longest follow up of patients. Our results are in agreement with the published results by Tiwari et al., 14 who demonstrated that the routine use of GM-CSF post transplant alters the prognostic significance of early lymphocyte recovery. 14 In DLBCL, lymphopenia at the time of diagnosis or relapse defined as an ALC of o1.0 Â 10 9 /L was an independent prognostic marker for OS. This was an independent prognostic factor irrespective of the international prognostic index. 15, 16 Furthermore, the use of rituximab improves OS in patients with a low ALC. 17 In the future; it would be interesting to see if specific lymphocyte subsets at the time of relapse can predict response to chemotherapy, as immune reconstitution involves several components of the immune response including reconstitution of functional B cells and effective APCs, reappearance of CTLs and NK cells that aid in eradication of minimal residual disease. 18 As rituximab becomes increasingly prominent in the treatment of DLBCL, understanding its impact on both long-term disease control as well as host immunity is critical. Recent studies have suggested that incorporation of rituximab into not only first-line therapy, but also salvage and even auto-SCT may result in improved outcomes. 4, 19 In conjunction with other chemotherapeutic regimens or auto-SCT, rituximab use has been associated with prolonged hypogammaglobulinemia and idiopathic neutropenia; however neither of these sequelae has been definitively associated with increased rate of infection. 20 Less clear, however, is the impact of rituximab on host immunity and subsequent risk of relapse. Specifically in DLBCL, loss of major histocompatibility class II expression was shown to correlate with worse outcome, theorized to be secondary to impaired host immunosurveillance. Infiltration of DLBCL by FOXP3 þ (T-regulatory) cells at the time of diagnosis was demonstrated to correlate with poor outcome. 21, 22 Though intriguing, both of these studies utilized primarily samples from the prerituximab era. As described above, the impact of rituximab on lymphocyte recovery and subsequent outcomes remains controversial; two prospective studies of rituximab suggest significantly different results. As rituximab becomes utilized in more patients and in multiple stages of treatment, it will be important to continue to evaluate the short-and longterm impact of rituximab treatment on host immune composition and capacity, particularly given the growing body of evidence supporting a critical host-lymphoma interaction. Future studies should evaluate the role of immunomodulatory drugs in an attempt to sustain the immunosurveillance effects among patients with large B-cell lymphoma.
In conclusion, this study demonstrates that rituximab does not have an impact on ALC at day 14 or 28 after auto-SCT for DLBCL. Rituximab may not hinder lymphocyte recovery and negatively affect immune reconstitution. The survival benefit with early lymphocyte recovery and prior rituximab exposure may be lost with longer follow up. Future studies should focus on lymphocyte subsets in the rituximab era. Our study is limited by the inherent weakness related to its retrospective nature. There is a need for prospective studies with posttransplant treatment interventions to prevent late relapses even in patients in the favorable group with prior rituximab exposure, and rapid early lymphocyte recovery after auto-SCT. 
